Thrombosis in the modern era of multiple myeloma

Abstract

In this issue of Blood, Bradbury et al report on behalf of the United Kingdom Medical Research Council (MRC), the results of a pooled, secondary analysis of thrombotic events in the Myeloma IX and XI trials, which tested immunomodulatory agents (IMiDs; thalidomide and lenalidomide) as treatments for newly diagnosed multiple myeloma (MM). The authors found that thrombosis was common, but generally not associated with inferior longer-term outcomes such as overall survival.1